糖尿病性黄斑缺血——一个新的治疗靶点?
本文综述糖尿病性黄斑缺血(DMI)的传统血管造影定义及其局限,提出基于视网膜毛细血管丛和脉络膜毛细血管相对灌注缺陷的血管表型假说,讨论缺氧、神经元-胶质-微血管交互等机制及动物模型不足,认为利用OCTA识别可逆性DMI表型可能是治疗干预成功的关键,并呼吁标准化OCTA灌注状态命名、开发新试验终点及开展自然史研究。
要点
- 传统基于黄斑无血管区扩大和不规则的DMI定义与分级并非视觉损害的替代标志物。
- 作者提出DMI存在基于各视网膜毛细血管丛和脉络膜毛细血管相对灌注缺陷的血管表型。
- 利用OCTA识别可逆性DMI表型可能是DMI治疗干预成功的关键,但需标准化OCTA灌注状态命名。
核心结论
- 作者认为利用OCTA识别可逆性DMI表型可能是DMI成功治疗干预的关键,但需标准化OCTA灌注状态命名。
- 作者认为视力不是DMI临床试验的理想终点,需在患者发生不可逆视力丧失前开发反映疾病进展的新试验终点。
- 作者认为需开展自然史研究以确定各血管和神经元参数的病程,从而定义DMI表型。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 传统DMI基于血管造影显示黄斑无血管区扩大和不规则来定义和分级,但这些解剖改变并非视觉损害的替代标志物。
- 作者假设DMI存在基于各视网膜毛细血管丛和脉络膜毛细血管相对灌注缺陷的血管表型。
- 本文强调了包括缺氧作用以及神经元、胶质细胞与微血管之间复杂关系在内的多条机制通路。
- 本文综述了现有动物模型并指出其不足。
- DMI表型可能部分解释糖尿病性黄斑水肿的发生和复发。
关键数值与推荐
- 传统DMI的定义和分级依据血管造影显示黄斑无血管区扩大和不规则。
- 视力不是DMI临床试验的理想终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文指出当前动物模型存在不足。
- 目前尚不清楚DMI在糖尿病视网膜病变严重程度分级中的位置和方式。
- 需标准化OCTA灌注状态命名。
- 需开发反映疾病进展的新试验终点。
- 需开展自然史研究以确定各血管和神经元参数的病程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic macular ischaemia (DMI) is traditionally defined and graded based on the angiographic evidence of an enlarged and irregular foveal avascular zone. However, these anatomical changes are not surrogate markers for visual impairment. We postulate that there are vascular phenotypes of DMI based on the relative perfusion deficits of various retinal capillary plexuses and choriocapillaris. This review highlights several mechanistic pathways, including the role of hypoxia and the complex relation between neurons, glia, and microvasculature. The current animal models are reviewed, with shortcomings noted. Therefore, utilising the advancing technology of optical coherence tomography angiography (OCTA) to identify the reversible DMI phenotypes may be the key to successful therapeutic interventions for DMI. However, there is a need to standardise the nomenclature of OCTA perfusion status. Visual acuity is not an ideal endpoint for DMI clinical trials. New trial endpoints that represent disease progression need to be developed before irreversible vision loss in patients with DMI. Natural history studies are required to determine the course of each vascular and neuronal parameter to define the DMI phenotypes. These DMI phenotypes may also partly explain the development and recurrence of diabetic macular oedema. It is also currently unclear where and how DMI fits into the diabetic retinopathy severity scales, further highlighting the need to better define the progression of diabetic retinopathy and DMI based on both multimodal imaging and visual function. Finally, we discuss a complete set of proposed therapeutic pathways for DMI, including cell-based therapies that may provide restorative potential.
引用
- Cheung CMG, Fawzi A, Teo KY, et al. Diabetic macular ischaemia- a new therapeutic target? Prog Retin Eye Res. 2021. PMID: 34902545. doi:10.1016/j.preteyeres.2021.101033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。